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Williams–Beuren syndrome (WBS) is a multisystemic neurodevelopmental disorder
caused by a hemizygous deletion on chromosome 7q11.23. Though at present there
is a limited number of reports on WBS patients with tumors, most cases are related
to blood cancer in children with WBS. We describe a case of Burkitt lymphoma in a
21-year-old man with WBS. In addition to providing a summary of published reports
describing tumors observed in patients with WBS, we present a hypothesis about
a possible mechanism of oncogenesis. In particular, we identified some significantly
dysregulated cancer-related genes using blood samples from this patient at the age of
19 years (who have not yet developed Burkitt lymphoma). Our findings may provide a
new perspective on the relation between WBS and Burkitt lymphoma.
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BACKGROUND
Williams–Beuren syndrome (WBS; MIM 194050) is a multisystemic neurodevelopmental disorder
caused by a microdeletion of chromosome 7q11.23 (Pober, 2010). The prevalence of WBS
is estimated as between 1 in 7500 and 1 in 20,000 individuals. WBS is characterized by a
highly variable phenotype, including “elfin face” appearance, supravalvular aortic stenosis (SVAS),
visuospatial deficits and hypersociability. Although there have been multiple case reports of
pediatric patients with WBS developing non-Hodgkin lymphoma (NHL), as of yet there is no
clear evidence of an association between WBS and lymphoma risk (Amenta et al., 2004; Thornburg
et al., 2005; Onimoe et al., 2011; Zhukova and Naqvi, 2013; Guenat et al., 2014; Vanhapiha et al.,
2014). It is possible that the low incidence of both these rare diseases conceals the relationship
between them. NHL is a heterogeneous group of lymphoid malignancies, 85–90% of which arise
from B lymphocytes (Shankland et al., 2012). Several different systems have been proposed for
classifying NHL subtypes according to their histological characteristics. Burkitt lymphoma is a
highly aggressive type of NHL and is the fastest growing human tumor (Molyneux et al., 2012).
Burkitt lymphoma is classified into three subtypes: endemic, sporadic, and immunodeficiency-
related Burkitt lymphoma. The sporadic type of Burkitt lymphoma occurs most commonly in
children aged 3–12 years (median 6–8 years) in region such as North America, northern and
eastern Europe, and east Asia and is 3.5 times more common in boys than in girls (Molyneux
et al., 2012). However, the precise molecular mechanism underlying the relation between Burkitt
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lymphoma and WBS has been unclear. Here we provide a
summary of published reports describing tumors in patients with
WBS and report a case of Burkitt lymphoma in a young adult with
WBS.
CASE PRESENTATION
We have been recruiting and following patients with WBS since
2012 in conjunction with our clinical research. In February 2014,
a 19-year-old male was admitted to our hospital to take part
in one of our clinical research projects. The patient had been
clinically diagnosed with WBS at the age of 1 year based on typical
clinical features, including the characteristic facial appearance.
We performed array-CGH analysis and detected a deletion
extending 1.4-Mb on chromosome 7q11.23 (Figure 1). Moreover,
we did not find any pathological copy number variations (CNVs)
other than 7q11.23. Laboratory data were normal: hemoglobin
(Hb) 15.9 g/dL, MCV 83.6 fL, MCH 30.3 p., MCHC 36.3%,
hematocrit (Hct) 43.8%, red blood cell (RBC) 5.24 × 106/µL,
white blood cell (WBC) 5.28 × 103/µL, neutrophils 56%,
lymphocytes 35%, eosinophils 0%, monocytes 9%, basophils
0%, and platelets 173 × 109/L. The patient was followed as
an outpatient in our hospital and was clinically assessed every
3 months. In October 2015, when the patient was 21 years
of age, he was admitted to our hospital with acute abdominal
pain. Abdominal computed tomography (CT) scans revealed
ileocecal intussusception by mass. An ileocecal resection was
performed. Immunohistochemistry (IHC) staining confirmed
strong positivity of CD20, CD10, and c-MYC. Serologic tests
for HIV and hepatitis B/C were all negative. Epstein-Barr-virus
IgG and EBNA1 IgG was positive. EBER was negative. The
biopsy confirmed the diagnosis of Burkitt lymphoma with a gene
breakpoint on MYC (8q24) determined by FISH. Cytogenetic
analysis revealed a karyotype of 46, XY, t(8;14) (q24.1;q32),
add(13) (q22)[8]/46, XY [12]. The patient received conventional
treatment for Burkitt lymphoma according to the LMB-96 group
C protocol, plus rituximab. In order to avoid complications,
the duration of therapy and doses of the agents were reduced.
However, despite of intensive chemotherapy, the patient passed
away in 2016.
MATERIALS AND METHODS
Participants and Informed Consent
This study was conducted according to the Declaration of
Helsinki; all participants provided written informed consent. The
local ethics committees of Kyoto University Graduate School of
Medicine and Osaka City General Hospital approved this study.
The demographic characteristics of participants are summarized
in Supplementary Table S1.
FIGURE 1 | CGH array analysis of the microdeletion in chromosome seven of a WBS patient. CGH array profile of chromosome seven revealing the heterozygous
deletion in 7q11.23.
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FIGURE 2 | Summary of case reports of tumors in WBS patients. The number of reported cases of blood cancer in patients with WBS has reached 11, and seven of
these were cases of Burkitt lymphoma.
FIGURE 3 | Expression levels of the selected five genes by qRT-PCR. The
relative expression level of each gene was normalized to that of the internal
control GAPDH from a WBS patient at the age of 19 years who have not yet
developed Burkitt lymphoma (red) and five age/sex-matched control subjects
(blue). Student’s t-test was used for the statistical analysis. ∗P-values < 0.05
were considered statistically significant.
DNA and RNA Isolation
Peripheral whole blood samples were taken and immediately
stored in an EDTA collection tube and PAXgene Blood RNA
tube (QIAGEN, Tokyo, Japan) for DNA and RNA extraction,
respectively. Total DNA was isolated using a QIAamp DNA
Blood Mini Kit (QIAGEN). RNA was extracted by using
a PAXgene Blood RNA system (QIAGEN) following the
manufacturer’s protocol. RNA quality was assessed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Tokyo, Japan).
CNV Analysis
Array-CGH was performed using an Agilent Sureprint
G3 CGH+SNP 4 × 180 K microarray (G4890A; Agilent
Technologies) following the manufacturer’s protocols. Briefly,
500 ng of purified DNA of a patient and a control (Agilent
Technologies) were double-digested with RsaI and AluI enzymes
(Agilent Technologies) for 2 h at 37◦C. Each digested sample
was labeled for 2 h with the Agilent Genomic DNA Labeling
Kit, using Cy5-dUTP for the patient DNA and Cy3-dUTP for
the control DNA. Labeled products were purified and prepared
according to the Agilent protocol. After probe denaturation and
pre-annealing with 50 ng of human Cot-1 DNA (Thermo Fisher
Scientific, Yokohama, Japan), hybridization was performed
at 65◦C for 24 h in a rotating oven. After washing steps, the
array slide was scanned with an Agilent Microarray Scanner
(G2565CA). The spot intensities were measured and the image
files quantified using the Agilent Feature Extraction 11.0.1.1
software. Text outputs from the quantitative analyses were
imported into Agilent CytoGenomics 4.0 software (Agilent
Technologies).
Gene Expression Analysis
A High Capacity cDNA Reverse Transcription Kit (Thermo
Fisher Scientific) was used to synthesize cDNA from 200 ng of
total RNA. qPCR was performed on the cDNA using an ABI 7900
HT Fast Real-Time PCR System (Thermo Fisher Scientific). Raw
threshold-cycle (Ct) values were obtained using SDS2.4 (Thermo
Fisher Scientific). The relative quantification of gene transcripts
was determined by the ddCt method. A standard curve was also
generated to evaluate the efficiency of the qPCR experiment. Each
sample was run in duplicate along with an endogenous control.
We assessed the appropriate reference gene using TaqMan probes
as endogenous controls. We selected GAPDH (Hs02758991_g1)
as the reference gene for validation, including randomly selected
genes. P-values were calculated by Student’s t-test. All primers
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used for the qRT-PCR analysis are listed in Supplementary
Table S2.
DISCUSSION
Here we report a clinical profile and possible molecular
mechanism of a 21-year-old male WBS patient who developed
Burkitt lymphoma. Recently, the number of reports of blood
cancer in patients with WBS has reached 11 cases, with 7 (64%)
of these being Burkitt lymphoma (Figure 2). Burkitt lymphoma
is the most common NHL of childhood (Hochberg et al., 2009).
In agreement with these epidemiological data, Burkitt lymphoma
in patients with WBS has been reported mostly in patients
under 10 years (Amenta et al., 2004; Thornburg et al., 2005;
Onimoe et al., 2011; Zhukova and Naqvi, 2013; Guenat et al.,
2014; Vanhapiha et al., 2014). However, in adolescents, Burkitt
lymphoma represents only approximately 20% of all NHL, and in
young adults this figure drops to 5–10% (Hochberg et al., 2009).
Chromosomal translocation t(8;14) (q24; q32) activates the
MYC oncogene and is the hallmark of Burkitt lymphoma
(Molyneux et al., 2012). However, MYC deregulation alone
seems to be insufficient for the malignant transformation, and
additional synergistic mutations are required (Havelange et al.,
2016). It is well known that GTF2I is located in the 7q11.23
region, which is interact with MYC (Roy et al., 1993). It
is also known that Burkitt lymphoma cells express surface
immunoglobulin M and B cell-associated antigens (CD19, CD20,
CD22, and CD79a). CD19 expression in particular has been
shown to promote MYC-dependent B cell lymphomagenesis
(Rickert, 2013). B cell lymphomas frequently dysregulate B cell
receptor (BCR) signaling, which plays an important role in B cell
proliferation and survival. Burkitt lymphomas critically depend
on the activation of “tonic” BCR signaling. BCR activation
can be influenced by a specific immunoglobulin structure, the
expression and mutations of adaptor molecules (such as BLNK),
and the activity of kinases (such as SYK, PI3K) or phosphatases
(such as PTEN) (Seda and Mraz, 2015). SWI/SNF or BAF
complexes mediate ATP-dependent chromatin remodeling to
regulate gene expressions that have recently been implicated in
human malignancies (Kadoch et al., 2013; Kadoch and Crabtree,
2015). Alterations of SWI/SNF genes clearly play an important
role in cancer development, progression, and/or resistance to
therapy (Masliah-Planchon et al., 2015).
To examine the expression levels of BCR signaling-related
genes (BLNK and CD19), SWI/SNF genes (BCL7B and
SMARCA4) and GTF2I gene, we performed qRT-PCR analysis
of blood samples from a WBS patient at the age of 19 years
(who have not yet developed Burkitt lymphoma) and five age/sex-
matched control subjects. We found that BCR signaling-related
genes (BLNK and CD19) were significantly upregulated in WBS
compared to control subjects (Figure 3). In addition, SWI/SNF
genes (BCL7B and SMARCA4) and GTF2I gene were significantly
dysregulated in WBS relative to the control subjects. The GTF2I
and BCL7B genes are located in the 7q11.23 region, which
is commonly deleted in WBS. The GTF2I gene is known to
be linked its deletion or missense mutation with cancerous
phenotype (Petrini et al., 2014; Guenat et al., 2017). The human
BCL7 gene family consists of BCL7A, BCL7B, and BCL7C.
A number of clinical studies have reported that members of the
BCL7 family are involved in cancer incidence, progression, and
development. A recent study suggested that BCL7B-deficiency
confers a risk of several malignancies, such as WBS, through
the Wnt Signaling pathway (Uehara et al., 2015; Decimi et al.,
2016). On the other hand, changes in the expression levels of BCR
signaling-related genes (BLNK and CD19) were more obvious
than changes in BCL7B gene expression. These findings suggest
that multiple WBS-related gene dysregulations may be involved
in the increased incidence of lymphoma among individuals with
WBS.
Burkitt lymphoma has a very high proliferation index, which
makes prompt diagnosis and initiation of therapy very important
to increase chances of survival (Shankland et al., 2012). Therefore,
early detection and treatment are important issues in Burkitt
lymphoma. Large and better-designed cohort studies are needed
to confirm a possible relationship between WBS and Burkitt
lymphoma.
CONCLUDING REMARKS
To our knowledge, this is the first reported case of a young adult
WBS patient with Burkitt lymphoma. Our findings will help to
provide an insight into the relation between WBS and Burkitt
lymphoma.
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